Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way

Incyte's now aiming for $3 billion in peak Jakafi sales—and $2 billion this year—but it's not stopping there. The company is preparing for several new launches, too, including a pemigatinib rollout that could come in 2020.